
Gabrielle Drolet is finding new ways to create with chronic pain
Only a month after publishing her first cartoon in The New Yorker, Gabrielle Drolet's chronic hand pain began. She was told it was just carpal tunnel syndrome, but the doctor was wrong — it quickly progressed into a debilitating disability that prevented her from drawing at all.
"Suddenly, every little task that you use your hands for without thinking about — sending a text, or chopping onions, or opening a can of beer — all of these things were really difficult on top of the career stuff," Drolet says in an interview with Q 's Tom Power.
"It was really crushing that suddenly I couldn't really draw," Drolet explains. "I tried to ignore the pain and just push myself, which made my symptoms much, much worse. I was just ignoring my limits, and I suffered the consequences of that for sure."
With her poignant grief and quirky sense of humour, Gabrielle Drolet processed her life-changing experience into a memoir. Her new book Look Ma, No Hands captures the overwhelming shock of when her chronic pain began, and balances it with comedic anecdotes about trying to navigate her new reality.
" Someone I knew had mentioned she was writing erotica for an app, and asked if I would be interested," Drolet says with a laugh. "And so I was doing it, but it just felt so silly because it was with voice-to-text. And it was summer, so it was so hot. But I felt as though I couldn't open my windows, because my neighbours would hear. Because we have shared balconies. So I'm steaming, I'm stewing in my office! And I'm reading these scenes just out loud to my computer. And that felt like a real low point for me, Tom."
Voice-to-text has been a crucial tool for making writing easier for Drolet. She wishes there was an accessible alternative for drawing as well, but there isn't. She's recovered as much as she could, but she still has to draw less often than she used to.
"My career generally — and especially my relationship with drawing — is different than it would be if I could draw all day without pain," says Drolet. "I would do it a lot more. But I have a very ergonomic setup. I take breaks, I stretch.… But yeah, it's still different." Like many people with a long-term disability, Gabrielle Drolet has gotten a lot of unsolicited and uninformed advice about how to fix her condition. She says that although these people have good intentions, they don't realize that they're trying to force a simple solution for a complex issue.
" With a young person, because it's not as common, people immediately think that there's a quick solution that I just haven't tried yet," says Drolet. "Immediately people jump to, 'Oh, take B-12', or 'Stretch!', or 'I have a great chiropractor.'
"And there was a while where I did take all of that advice. Because I was like, 'OK, the next thing I try is gonna be the thing that heals me.' And that's just not how it works for a lot of people, unfortunately," the author explains.
Although it's been an intense journey, Gabrielle Drolet no longer spends time wishing that her condition would go away. She still takes moments to acknowledge her loss, but ultimately, she realized she had to make peace with the new path her life has taken.
"There's no point in continuing to dwell on it.… I gotta keep it moving," says Drolet. "There will always still be moments of wondering where my life would have been if that hadn't happened. But also there's been so much good that's come from it. You know, I moved to Montreal. I adopted a pigeon."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
42 minutes ago
- CTV News
Ben Sweet plans to cycle across Canada in 11 days
Coldwater's Ben Sweet plans to cycle 5,800 kilometres across Canada in 11 days to raise funds for cancer research.

National Post
an hour ago
- National Post
Satellos Bioscience to Participate in PPMD's Annual Conference in Las Vegas
Article content TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (' Satellos ' or the ' Company '), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las Vegas, Nevada. Article content The PPMD Annual Conference brings together families, researchers, clinicians, and companies committed to improving outcomes for people living with Duchenne. Satellos will be onsite to engage with the Duchenne community, listen to families' experiences, and share updates on its science and mission to regenerate muscle from within. Article content Article content 'We're looking forward to connecting in person with families and advocates who are at the heart of this work,' said Frank Gleeson, Co-founder and CEO of Satellos. 'This conference is a powerful reminder of why we're focused on developing a new approach to treat Duchenne — one that aims to restore the body's ability to repair muscle.' Article content Attendees can meet members of the Satellos team throughout the event and learn more by visiting the company's booth in the exhibition hall. Article content About Satellos Bioscience Inc. Article content Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. By restoring this missing dystrophin signal in DMD, SAT-3247 enables muscle stem cells to divide properly and more efficiently, promoting natural muscle repair and regeneration. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Satellos also is leveraging its proprietary discovery platform MyoReGenX™ to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. For more information, visit Article content This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases; its/their prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos' technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are 'forward-looking information or statements.' Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'believe', 'plan', 'expect', 'intend', 'estimate', 'anticipate', 'potential', 'prospective' , 'assert' or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), and the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management's ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks listed in the 'Risk Factors' section of Satellos' Annual Information Form dated March 26, 2025 (which is located on Satellos' profile at Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise. Article content Article content Article content Article content Article content Contacts Article content Investors: Article content Liz Williams, CFO, Article content ir@ Article content Article content Media: Article content Emily Williams, Senior Director, Communications, Article content Article content Article content


Globe and Mail
2 hours ago
- Globe and Mail
Happy Belly Food Group's Heal Wellness QSR Announces Securing a Real-Estate Location in the City of Charlottetown, Prince Edward Island
Toronto, Ontario--(Newsfile Corp. - June 16, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce that just two weeks following our May 27th news release regarding the signing of a franchisee for the province of Prince Edward Island (" PEI"), we have secured a prime real estate location in the City of Charlottetown, PEI. The franchisee is an experienced multi-unit, multi-branded operator who currently owns both Lettuce Love Café and HEAL Wellness in Westdale, Hamilton. We anticipate the Charlottetown location to open in late Q3 2025. Heal Wellness (" Heal") is a quick-service restaurant (" QSR") brand specializing in fresh smoothie bowls, açaí bowls, and smoothies. To view an enhanced version of this graphic, please visit: "In under four months Happy Belly has announced an area development agreement for Heal in Atlantic Canada, signed multiple franchisees, and now signed their 1 st prime real estate location for Heal to be opened in Charlottetown, PEI", said Sean Black, Chief Executive Officer. "We are ready to begin the initial stages of construction for this location and to welcome an experienced franchisee who is now expanding with Happy Belly. We are inspired by the growth of our franchise partners-taking on more brands and more locations-which further validates the strength of our emerging brand portfolio and the reliable foundation our franchising program provides. As summer begins, we look forward to accelerating this momentum with additional franchise agreements across Canada. Securing Heal's first real estate location on the East Coast represents a major milestone in our national expansion strategy." To view an enhanced version of this graphic, please visit: "With every new agreement signed, Heal Wellness continues to emerge as the 1 st true national smoothie bowl brand with a coast to coast presence. As we enter the back half of 2025, our priority remains on accelerating growth through a combination of organic development and targeted acquisitions. With a growing number of restaurants in the pipeline across Canada, we anticipate announcing additional projects in the coming months as we continue to lock in new franchise partnerships and secure high-quality real estate. These advancements reflect meaningful progress toward our vision of building a disciplined and scalable growth platform. Currently, Happy Belly has 551 retail franchise locations contractually committed across our portfolio of emerging brands-spanning those in planning, under construction, or already in operation. We are actively growing this pipeline into 2025 and 2026, consistently aligning with the right partners and locations to bring our development strategy to life." We are just getting started. About Heal Wellness Heal Wellness was founded with a passion and mission to provide quick, fresh wellness foods that support a busy and active lifestyle. We currently offer a diverse range of smoothie bowls and smoothies. We take pride in meticulously selecting every superfood ingredient on our menu to fuel the body, including acai smoothie bowls, smoothies, and super-seed grain bowls. Our smoothie bowls are crafted with real fruit and enriched with superfoods like acai, pitaya, goji berries, chia seeds, and more. Franchising For franchising inquiries please see or contact us at hello@ About Happy Belly Food Group Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company") is a leader in acquiring and scaling emerging food brands across Caasdnada. Happy Belly Food Group To view an enhanced version of this graphic, please visit: Sean Black Chief Executive Officer Shawn Moniz Chief Operating Officer FOR FURTHER INFORMATION, PLEASE VISIT: www: or email hello@ If you wish to contact us please call: 1-877-589-8805 Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management. Cautionary Note Regarding Forward-Looking Statements All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws. Forward-Looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include the future performance of Happy Belly and her subsidiaries. Forward-Looking statements are based on the opinions and estimates at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. There are no assurances that the business plans for Happy Belly described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on